The PennZone

  • Home
  • Business
  • Non-profit
  • Real Estate
  • Health
  • Technology
  • Construction
  • Travel
  • Legal

Actuated Medical Developing Technology to Improve Targeting for Next-Generation Alcohol Use Disorder Treatments
The PennZone/10278266

Trending...
  • Still Using Ice? FrostSkin Reinvents Hydration
  • Cold. Clean. Anywhere. Meet FrostSkin
  • Patron Saints Of Music Names Allie Moskovits Head Of Sync & Business Development
Actuated Medical Inc.
BELLEFONTE, Pa. - PennZone -- Treating alcohol misuse remains a major challenge worldwide.  Given the diverse biological processes that contribute to alcohol use disorder, new medications are needed to provide a broader spectrum of treatment options. Some people may respond to a medication that helps with craving, others may respond to a medication that relieves impulsivity, others may respond to a medication that reverses the negative emotional state of withdrawal or protracted withdrawal. Just like any other medical condition, people with alcohol use disorder deserve to have a range of treatment options available to them. Scientists are working to develop a larger menu of pharmaceutical treatments that could be tailored to individual needs.

Actuated Medical's innovative NeuralGlider Injector will enable the delivery of next-generation medications into small targets deep in the brain, to fundamentally change the trajectory of alcohol use disorder and improve outcomes.  The goal is to deliver a therapeutic that will damp down cravings enough for other therapies to have a chance to work.  The therapeutic gets delivered accurately to the target and stays there.

Actuated Medical, Inc. has been awarded a $3 million pre-clinical Phase II Small Business Innovative Research (SBIR) grant from the National Institutes of Health-National Institute on Alcohol Abuse and Alcoholism to develop the "Oscillated Insertion Tool for Minimally Invasive, Low-Damage, Accurate Placement of Delivery Cannula to Improve Efficacy for DREADDS (designer receptors exclusively activated by designer drugs) Therapy in Alcohol Addiction Treatment" which will be commercially recognized as the NeuralGlider Injector.

More on The PennZone
  • Kobie Wins for AI Innovations in the 2026 Stevie® Awards for Sales & Customer Service
  • Author Jeff Bogle to Host Street Cats Mediterranean Cruise Featuring Cat Behaviorist Molly DeVoss
  • Berman | Sobin | Gross LLP Celebrates 35 Years of Advocating for Maryland's Injured Workers and Families
  • Art of Whiskey Hosts 3rd Annual San Francisco Tasting Experience During Super Bowl Week
  • Kilmaine Saints to Anchor St. Patrick's Day Weekend with Live Album Recording at XL Live

"Many of us know someone who is dealing with an alcohol addiction and have felt helpless as we watched them suffer. That is why we are so excited to develop and commercialize our NeuralGlider Injector technology as it may one day help to offer a more effective treatment option for those afflicted with alcohol use disorder." Maureen L. Mulvihill, Ph.D., Actuated Medical President, CEO, & Co-Founder.

About Actuated Medical, Inc.

Actuated Medical is a Pennsylvania medical device product innovator founded in 2006 on the entrepreneurial idea that electronically controlled motion can solve clinical needs and improve patient outcomes. They are developing products in the areas of neuroscience, critical care, gastroenterology, and pediatrics. Their Actuated Neuroscience Division focuses on developing tools to assist researchers in understanding neurological conditions. Recently, they were awarded a 5-year Contract under the National Institutes of Health (NIH) Blueprint MedTech (BPMT) initiative to assist brain researchers conduct their FDA compliant testing. Actuated has 42 issued patents and 7 FDA 510(k) clearances. They have been the recipient of a 2014 & 2020 SBA Tibbets Awards for SBIR commercialization excellence. Actuated's CEO was the 2020 Life Sciences Pennsylvania CEO of the Year due to the teams Covid PPE pivot.

More on The PennZone
  • PADT Earns Prestigious 2025 Americas Customer Loyalty Award from Ansys, Part of Synopsys
  • Florida Keys Visitors Can Save 15 Percent With KeysCaribbean's Advanced Booking Discount
  • Sleep Basil Unveils Revamped Natural Latex Mattress Collection Page for Cooler, Cleaner, Better-Aligned Sleep
  • Conexwest Delivers Custom Shipping Container MRI Lab, Saving California Hospital an Estimated $9 Million in Renovation Costs
  • Smallville, Sailor Moon, Reno 911! Stars Added To FAN EXPO Philadelphia Lineup, May 29-31

More information about Actuated neural device innovations.

See www.actuatedneuroscience.com

NIH Disclaimer.

Research reported in this publication was supported by the National Institute On Alcohol Abuse And Alcoholism of the National Institutes of Health under Award Number R44AA030512. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

###

For more information about this topic, please contact Maureen L. Mulvihill, Ph.D. by phone at 814-355-0003 or email at info@actuatedmedical.com.

Additional information can be found by visiting:

https://actuatedmedical.com

https://actuatedneuroscience.com

Contact
Actuated Medical
***@actuatedmedical.com


Source: Actuated Medical, Inc.

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Atlanta Magazine Names Dr. Rashad Richey One of Atlanta's Most Influential Leaders in 2026 as the FIFA World Cup Approaches
  • Apostle Margelee Hylton Announces the Release of Third Day Prayer
  • Slotozilla Reports Strong Q4 Growth and Sigma Rome Success
  • "Lights Off" and Laughs On: Joseph Neibich Twists Horror Tropes in Hilariously Demonic Fashion
  • Families Gain Clarity: Postmortem Pathology Expands Private Autopsy Services in St. Louis
  • Beethoven: Music of Revolution and Triumph - Eroica
  • Don't Get Burned by High Heater Prices in Philly This Winter!
  • Amy Turner Receives 2025 ENPY Partnership Builder Award from The Community Foundation
  • Hubble Tension Solved? Study finds evidence of an 'Invisible Bias' in How We Measure the Universe
  • Boonuspart.ee Acquires Kasiino-boonus.ee to Strengthen Its Position in the Estonian iGaming Market
  • Vines of Napa Launches Partnership Program to Bolster Local Tourism and Economic Growth
  • Finland's €1.3 Billion Digital Gambling Market Faces Regulatory Tug-of-War as Player Protection Debate Intensifies
  • Angels Of Dirt Premieres on Youtube, Announces Paige Keck Helmet Sponsorship for 2026 Season
  • Still Using Ice? FrostSkin Reinvents Hydration
  • Patron Saints Of Music Names Allie Moskovits Head Of Sync & Business Development
  • Dave Aronberg Named 2026 John C. Randolph Award Recipient by Palm Beach Fellowship of Christians & Jews
  • General Relativity Challenged by New Tension Discovered in Dark Siren Cosmology
  • Burkentine Real Estate Group to Bring A New Community to Millersville, Pennsylvania
  • Unseasonable Warmth Triggers Early Pest Season Along I-5 Corridor
  • VIP Vacations Named Winner in 2026 WeddingWire Couples' Choice Awards®

Popular on PennZone

  • Mark Schork Selected As 'Board Observer' By Philadelphia Bar Foundation - 183
  • Michael Judkins Releases New Poetry Book, Deeper Than You Think
  • $80 Million Revenue Backlog for AI Cybersecurity Company Building the Future of Integrated Cybersecurity and Public Safety: $CYCU
  • Still Using Ice? FrostSkin Reinvents Hydration
  • Accountants Near Me Cheyenne Opens U.S. Directory for Accountants, Bookkeepers and Tax Services
  • NOW OPEN - New Single Family Home Community in Manalapan
  • Precision Adult Care Expands 24/7 Adult In-Home Care Services to Meet Growing Demand in the Coachella Valley
  • Why 'Instant-Liquidity' Gaming is Dominating the Nordic Tech Demographic
  • Boston Industrial Solutions' Natron® 512N Series UV LED Ink Earns CPSIA Certification
  • 2025 Top Lawyers - ELA Awards by Expert Law Attorneys

Similar on PennZone

  • Conexwest Delivers Custom Shipping Container MRI Lab, Saving California Hospital an Estimated $9 Million in Renovation Costs
  • FDA Meeting Indicates a pivotal development that could redefine the treatment landscape for suicidal depression via NRx Pharmaceuticals: $NRXP
  • $2.7 Million 2025 Revenue; All Time Record Sales Growth; 6 Profitable Quarters for Homebuilding Industry: Innovative Designs (Stock Symbol: IVDN)
  • CCHR: Decades of Warnings, Persistent Inaction; Studies Raise New Alarms on Psychiatric Drug Safety
  • Arbutus Medical Raises C$9.3M to Accelerate Growth of Surgical Workflow Solutions Outside the OR
  • Families Gain Clarity: Postmortem Pathology Expands Private Autopsy Services in St. Louis
  • High-Margin Energy & Digital Infrastructure Platform Created after Merger with Established BlockFuel Energy, Innovation Beverage Group (NAS DAQ: IBG)
  • Diveroli Investment Group Files 13D in PetMed Express, Highlights Strategic Value, Asset Floor, and Multiple Takeover Pathways
  • VC Fast Pitch Is Coming to Maryland on March 26th
  • Aleen Inc. (C S E: ALEN.U) Advances Digital Wellness Vision with Streamlined Platform Navigation and Long-Term Growth Strategy
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us